Decent Organic Sales Growth Expected for Abbott Laboratories (ABT) in 2026

Abbott Laboratories (NYSE:ABT) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds.

On January 23, Larry Biegelsen from Wells Fargo maintained an Overweight rating on Abbott Laboratories (NYSE:ABT). However, the analyst lowered the target price on the stock from $146 to $122. Following this, the stock now offers an upside potential of 15% from the current level.

Romaset/Shutterstock.com

Biegelsen noted some transitory headwinds faced by the business, due to which the company missed consensus sales estimates for the fourth quarter. Although the management has provided guidance of 6.5%-7.5% organic growth in sales during 2026, it still remains below the prior consensus. The analyst attributed these estimates to Nutrition headwinds that are likely to persist during the first half of the year.

On January 23, Joanne Wuensch from Citi also reiterated his Buy rating for Abbott Laboratories (NYSE:ABT) and cut his target price from $155 to $140. This revision follows the company’s Q4 announcement, and the analyst highlighted the need for improved results going forward for the stock to regain momentum.

Abbott Laboratories (NYSE:ABT) is a leading name in the healthcare industry that is involved in discovering, developing, and marketing healthcare products across the globe. The business is segregated into four segments, i.e., Diagnostic Products, Established Pharmaceutical Products, Medical Devices, and Nutritional Products.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.